Replimune

REPLPhase 3

Woburn, United StatesFounded 2015replimune.com

Founded in 2015, Replimune is at the forefront of developing next-generation oncolytic immunotherapies with the mission to revolutionize cancer treatment. Its lead candidate, RP1 (vusolimogene odeparepvec), has a PDUFA date of July 22, 2025, for advanced melanoma and is being studied across multiple skin cancers. The company's wholly-owned RPx platform and in-house manufacturing capability position it to develop a broad portfolio of treatments aimed at overcoming resistance to current immunotherapies.

Market Cap

$576.4M

Founded

2015

Focus

BiologicsViral Technology

REPL · Stock Price

USD 6.989.01 (-56.35%)

Historical price data

AI Company Overview

Technology Platform

The RPx platform is a next-generation, HSV-1-based oncolytic immunotherapy platform engineered for direct tumor cell destruction and induction of a potent, systemic anti-tumor immune response through the expression of immune-activating transgenes.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Vusolimogene Oderparepvec + Nivolumab + Nivolumab + Relatlimab + Pembrolizumab +...	Advanced Melanoma	Phase 3
RP2 + Ipilimumab + Nivolumab	Metastatic Uveal Melanoma	Phase 2/3
RP2 + Pegfilgrastim + Filgrastim	Gastric Adenocarcinoma	Phase 2
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 Monotherapy	Hepatocellular Carcinoma	Phase 2
Vusolimogene Oderparepvec (VO) + Pembrolizumab	Angiosarcoma	Phase 2

Opportunities

Major near-term opportunity with the PDUFA date for RP1 in advanced melanoma on July 22, 2025.

Broad pipeline expansion into high-need areas like uveal melanoma, HCC, and skin cancers in immunocompromised patients provides multiple growth vectors.

The wholly-owned platform and manufacturing enable rapid development of new candidates and control over commercial supply.

Risk Factors

Key risks include clinical/regulatory failure of lead candidate RP1, execution challenges in transitioning to a commercial-stage company, significant ongoing cash burn requiring future financing, and intense competition in the oncology immunotherapy landscape.

Competitive Landscape

Competes with Amgen's T-VEC (first-generation oncolytic virus) and numerous clinical-stage biotechs in the oncolytic virus space. Primary competition comes from other immunotherapies and targeted therapies in specific tumor types. Differentiation lies in Replimune's next-generation, potent HSV-1 platform capable of treating deep tumors and its strategy of combination therapy from the outset.

Publications

Patents

Pipeline